» Articles » PMID: 22537421

Effect of Hemoglobin Target on Progression of Kidney Disease: a Secondary Analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) Trial

Overview
Journal Am J Kidney Dis
Specialty Nephrology
Date 2012 Apr 28
PMID 22537421
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Conflicting relationships have been described between anemia correction using erythropoiesis-stimulating agents and progression of chronic kidney disease (CKD). This study was undertaken to examine the impact of target hemoglobin level on progression of kidney disease in the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial.

Study Design: Secondary analysis of a randomized controlled trial.

Setting & Participants: 1,432 participants with CKD and anemia.

Intervention: Participants were randomly assigned to target hemoglobin levels of 13.5 versus 11.3 g/dL with the use of epoetin alfa.

Outcomes & Measurements: Cox regression was used to estimate HRs for progression of CKD (a composite of doubling of creatinine level, initiation of renal replacement therapy, or death). Interactions between hemoglobin target and select baseline variables (estimated glomerular filtration rate, proteinuria, diabetes, heart failure, and smoking history) also were examined.

Results: Participants randomly assigned to higher hemoglobin targets experienced shorter time to progression of kidney disease in both univariate (HR, 1.25; 95% CI, 1.03-1.52; P = 0.02) and multivariable models (HR, 1.22; 95% CI, 1.00-1.48; P = 0.05). These differences were attributable to higher rates of renal replacement therapy and death for participants in the high hemoglobin arm. Hemoglobin target did not interact with estimated glomerular filtration rate, proteinuria, diabetes, or heart failure (P > 0.05 for all). In the multivariable model, hemoglobin target interacted with tobacco use (P = 0.04) such that the higher target had a greater risk of CKD progression for participants who currently smoked (HR, 2.50; 95% CI, 1.23-5.09; P = 0.01), which was not present for those who did not currently smoke (HR, 1.15; 95% CI, 0.93-1.41; P = 0.2).

Limitations: A post hoc analysis; thus, cause and effect cannot be determined.

Conclusions: These results suggest that a high hemoglobin target is associated with a greater risk of progression of CKD. This risk may be augmented by concurrent smoking. Further defining the mechanism of injury may provide insight into methods to optimize outcomes in anemia management.

Citing Articles

Anemia and Hypoxia Impact on Chronic Kidney Disease Onset and Progression: Review and Updates.

Habas Sr E, Al Adab A, Arryes M, Alfitori G, Farfar K, Habas A Cureus. 2023; 15(10):e46737.

PMID: 38022248 PMC: 10631488. DOI: 10.7759/cureus.46737.


Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.

Chung E, Palmer S, Saglimbene V, Craig J, Tonelli M, Strippoli G Cochrane Database Syst Rev. 2023; 2:CD010590.

PMID: 36791280 PMC: 9924302. DOI: 10.1002/14651858.CD010590.pub3.


Risk improvement and adverse kidney outcomes in patients with chronic kidney disease: findings from KNOW-CKD.

Koh H, Kim H, Jung C, Lee Y, Park J, Yoo T J Nephrol. 2022; 36(3):767-776.

PMID: 36434262 DOI: 10.1007/s40620-022-01502-x.


Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors.

Locatelli F, Minutolo R, De Nicola L, Del Vecchio L Drugs. 2022; 82(16):1565-1589.

PMID: 36350500 PMC: 9645314. DOI: 10.1007/s40265-022-01783-3.


Association between hemoglobin and chronic kidney disease progression: a secondary analysis of a prospective cohort study in Japanese patients.

Pan W, Han Y, Hu H, He Y BMC Nephrol. 2022; 23(1):295.

PMID: 35999502 PMC: 9400271. DOI: 10.1186/s12882-022-02920-6.


References
1.
Petitti D, Wingerd J, Pellegrin F, RAMCHARAN S . Oral contraceptives, smoking, and other factors in relation to risk of venous thromboembolic disease. Am J Epidemiol. 1978; 108(6):480-5. DOI: 10.1093/oxfordjournals.aje.a112646. View

2.
Johnson D, Pat B, Vesey D, Guan Z, Endre Z, Gobe G . Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int. 2006; 69(10):1806-13. DOI: 10.1038/sj.ki.5000356. View

3.
Zhang X, Zhang M . SAS macros for estimation of direct adjusted cumulative incidence curves under proportional subdistribution hazards models. Comput Methods Programs Biomed. 2010; 101(1):87-93. PMC: 3377442. DOI: 10.1016/j.cmpb.2010.07.005. View

4.
Gouva C, Nikolopoulos P, Ioannidis J, Siamopoulos K . Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004; 66(2):753-60. DOI: 10.1111/j.1523-1755.2004.00797.x. View

5.
Keane W, Zhang Z, Lyle P, Cooper M, de Zeeuw D, Grunfeld J . Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol. 2007; 1(4):761-7. DOI: 10.2215/CJN.01381005. View